How effective is Ribociclib?

Ribociclib (Ribociclib) was found to be effective in three major studies in women with HR-positive, HER2-negative advanced cancer. In one major study, 668 postmenopausal women with advanced cancer who had not received prior treatment received letrozole (an aromatase inhibitor) plus reboxil or placebo. Women who took rebociclib and letrozole lived an average of 25.3 months without worsening of their condition, while women who took placebo and letrozole lived for an average of 16.0 months.

Another major study involved495 premenopausal women with advanced breast cancer who had not received prior treatment received Goserelin (an LHRH inhibitor) plus letrozole or anastrozole (an aromatase inhibitor) plus reboxil or placebo. Women who took reboxil lived an average of 27.5 months without disease progression, compared with 13.8 months for women who took a placebo. A further study involved 726 postmenopausal women who had either had no previous treatment or had only received hormone therapy (to reduce the effects of estrogen). Patients received fulvestrant plus reboxil or placebo. Patients taking reboxil and fulvestrant survived an average of 20.6 months

The original drug Riboxil has been launched in China, but due to its short time on the market, its price and purchase methods are not yet known, and it has not yet been included in the scope of medical insurance. The price of the European version of Riboxil's original drug, 200mg*21 tablets, sold overseas may be more than RMB 20,000 per box, while the Indian version of Riboxil's original drug, 200mg*21 tablets, may be priced around RMB 3,000 per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same. There are currently no generic versions of Riboxil produced and marketed.